E. Muyzhnek, V. Kiselev, O. Jakobs, N. Rozhkova, A. Kaprin, I. I. Burdina, S. B. Zapirova, M. Mazo, S. Prokopenko, P. G. Labazanova
{"title":"FIBROSCLEROSIS AND SCLEROSING ADENOSIS WITH MICROCALCIFICATIONS IN THE BREAST. MOLECULAR PATHOGENESIS, TIMELY DIAGNOSIS AND TREATMENT","authors":"E. Muyzhnek, V. Kiselev, O. Jakobs, N. Rozhkova, A. Kaprin, I. I. Burdina, S. B. Zapirova, M. Mazo, S. Prokopenko, P. G. Labazanova","doi":"10.17709/2409-2231-2019-6-2-8","DOIUrl":null,"url":null,"abstract":"A brief review of current data on the generality of the epidemiology and molecular pathogenesis of breast cancer and benign breast diseases is presented. Currently, a type of mastopathy, fibrosclerosis/sclerosing adenosis, accompanied by the formation of microcalcifications, is considered as a benign pathological condition with a high risk of malignancy, and also as a pre-start condition of a possible transition of mastopathy to cancer. In the review is discussed the fundamental biological process of the epithelial-mesenchymal transition (EMT) as a molecular pathogenetic basis of this phenomenon. Identification of the above mentioned pathological changes using mammography and refined diagnostics using a vacuum aspiration biopsy allow timely treatment of fibrosclerosis and sclerosing adenosis with Indinol® Forto, a drug of pathogenetic action based on indole-3-carbinol, due to its multiple anticancer and oncoprophylactic activity, including ability to reverse at the epigenetic level the EMT process abnormally proceeding in these benign breast diseases.","PeriodicalId":119961,"journal":{"name":"Research'n Practical Medicine Journal","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research'n Practical Medicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17709/2409-2231-2019-6-2-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
A brief review of current data on the generality of the epidemiology and molecular pathogenesis of breast cancer and benign breast diseases is presented. Currently, a type of mastopathy, fibrosclerosis/sclerosing adenosis, accompanied by the formation of microcalcifications, is considered as a benign pathological condition with a high risk of malignancy, and also as a pre-start condition of a possible transition of mastopathy to cancer. In the review is discussed the fundamental biological process of the epithelial-mesenchymal transition (EMT) as a molecular pathogenetic basis of this phenomenon. Identification of the above mentioned pathological changes using mammography and refined diagnostics using a vacuum aspiration biopsy allow timely treatment of fibrosclerosis and sclerosing adenosis with Indinol® Forto, a drug of pathogenetic action based on indole-3-carbinol, due to its multiple anticancer and oncoprophylactic activity, including ability to reverse at the epigenetic level the EMT process abnormally proceeding in these benign breast diseases.